MASP2 and thrombotic microangiopathy: The only clinically available MASP inhibitor is narsoplimab (Omeros and Lonza; Basel, CH), targeting MASP2, and was granted FDA Breakthrough Therapy and Organ Drug designations for thrombotic microangiopathies [94].